Allegations of Fraud and Corruption Loom Over State-Owned Enterprises' Stocks

May 24, 2024, 10.25 PM

ILUSTRASI. Penjualan Indofarma tumbuh. Suasana di pabrik farmasi PT Indofarma Tbk (INAF) di Cibitung, Jawa Barat (10/4). Saat ini kapasitas produksi berjalan 100 persen meliputi 2,3 milyar tablet serta 250 juta kapsul pertahun. Indofarma akan melakukan investasi sebesar Rp 100 miliar untuk pengembangan produksi generik dan herbal, serta pemenuhan kebutuhan bahan baku yang saat ini sekitar 90 persen masih impor. Pada triwulan pertama tahun 2012 pabrik farmasi ini tumbuh 50 persen dari triwulan 2011 yakni sekitar Rp 111 miliar. KONTAN/Muradi/10/04/2012

Reporter: Pulina Nityakanti | Editor: Syamsul Azhar

- JAKARTA. A wave of negative news is currently sweeping over the stocks of state-owned enterprises (SOEs) in Indonesia. Not only are these companies grappling with financial issues and high debt burdens, but allegations of corruption and fraud are also surfacing. This could potentially erode investor confidence in these red-plate issuers.

Thanks for reading Kontan English.

Please create account or log in.

Only Rp5,000 to continue reading.

BUY NOW!